ALS News Today Home | ALS News Today
WEBSep 5, 2024 · S-oxprenolol, an investigational therapy being developed by Actimed Therapeutics to treat muscle wasting in amyotrophic lateral sclerosis (ALS), has been granted orphan drug status in the U.S. That designation, awarded by the U.S. Food and Drug Administration, is given to therapies intended to treat rare diseases, like ALS, that….
How Common Is ALS? - ALS News Today
WEBSep 28, 2019 · The average incidence rate of ALS worldwide is about one in 50,000 people per year that equates to about 5,760 to 6,400 new diagnoses per year. The average age of onset of the disease is about 60 years, with men at a slightly higher risk compared to women (a male-to-female ratio of 1.5 to 1). However, with …
Landmark ACT for ALS Act on President’s Desk - ALS News Today
WEBDec 22, 2021 · The legislation (), which has passed the U.S. House and most recently the Senate, also would create a U.S. Food and Drug Administration (FDA) Rare Neurodegenerative Disease Grant Program to support other research and development in the field of ALS and other severely debilitating neurodegenerative diseases.The ACT for ALS Act, which will make available $100 million annually from 2022 to 2026 ...
News Archives - ALS News Today
WEBDewpoint Therapeutics has won a second grant from Target ALS Foundation to advance preclinical studies of its experimental TDP-43-targeted therapy for amyotrophic lateral sclerosis (ALS). TDP-43 is a protein that often gets mislocalized within cells in ALS and forms into toxic clumps that contribute to neurodegeneration. Dewpoint’s….
Bulbar-onset ALS in Elderly Patients May Lead to Shorter Survival...
WEBOct 2, 2018 · Bulbar-onset amyotrophic lateral sclerosis (ALS) is the most common form of the disease among patients 80 and older at disease onset, a factor that seems to contribute to shorter survival for these patients compared with younger ALS patients, a retrospective study has found. The study, “ Very late-onset amyotrophic lateral sclerosis in a ...
Living With ALS - ALS News Today
WEBAmyotrophic lateral sclerosis (ALS) is a progressive muscle-wasting condition that has no cure. Living with ALS and coming to terms with the diagnosis can be a challenge. It means adapting to a new way of life, but with the support of others and the advancements in science, it is possible to maintain the best possible quality of life.
ALS News Today Forums
WEBFlash Briefings. This forum is a place to store the new flash briefings offered by ALS News Today. 1 year, 10 months ago. Viewing 1 - 9 of 9 forums.
ALS Facts and Statistics – ALS News Today
WEBThe disease is most common among people 60 years or older, but nearly 10 percent of ALS patients are 45 or younger. Although ALS is 20 percent more likely to develop in men than in women, with advancing age, the gender difference disappears. Moreover, Caucasians and non-Hispanics are more likely to develop ALS compared with other ethnic groups.
FDA Gives ET-101, Gene Therapy for ALS, Orphan Drug Status
WEBNov 15, 2022 · ET-101, also known as SynCav1, is designed to deliver a copy of the Caveolin-1 gene to nerve cells using a harmless viral vector.This gene provides the instructions for producing a protein with the same name that helps organize and regulate receptors involved in nerve cell communication.
Phase 1 clinical trial of experimental ALS therapy AKV9 to soon...
WEBAug 28, 2023 · Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic lateral sclerosis (ALS), in healthy people. The trial follows the clearance of Akava’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). It will be AKV9’s first-in-human study and is ...